BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 StudyDavid Lavie, Rosa Ayala, Jesús María Hernández‐Rivas et al.|Blood|2023Cited by 7
BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 StudyRosa Ayala, David Lavie, Nieves López‐Muñoz et al.|Blood|2022Cited by 4
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II StudyRosa Ayala, David Lavie, Nieves López‐Muñoz et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 2